Download PDF
Synlett 2012; 23(18): 2677-2681
DOI: 10.1055/s-0032-1317346
letter
© Georg Thieme Verlag Stuttgart · New York

Formal Total Synthesis of (–)-5,6-Dihydrocineromycine B

G. Venkateswar Reddy
Division of Natural Product Chemistry, CSIR - Indian Institute of Chemical Technology, Hyderabad – 500007, India   Fax: +91(40)27160512   Email: suresh@iict.res.in
,
R. Sateesh Chandra Kumar
Division of Natural Product Chemistry, CSIR - Indian Institute of Chemical Technology, Hyderabad – 500007, India   Fax: +91(40)27160512   Email: suresh@iict.res.in
,
B. Siva
Division of Natural Product Chemistry, CSIR - Indian Institute of Chemical Technology, Hyderabad – 500007, India   Fax: +91(40)27160512   Email: suresh@iict.res.in
,
K. Suresh Babu
Division of Natural Product Chemistry, CSIR - Indian Institute of Chemical Technology, Hyderabad – 500007, India   Fax: +91(40)27160512   Email: suresh@iict.res.in
,
J. Madhusudana Rao*
Division of Natural Product Chemistry, CSIR - Indian Institute of Chemical Technology, Hyderabad – 500007, India   Fax: +91(40)27160512   Email: suresh@iict.res.in
› Author Affiliations
Further Information

Publication History

Received: 13 July 2012

Accepted after revision: 11 September 2012

Publication Date:
18 October 2012 (online)

    Permissions and Reprints All articles of this category


Abstract

An efficient and highly convergent formal total synthesis of the 14-membered macrolide (–)-5,6-dihydrocineromycine B is achieved. Key reaction sequences include a Sharpless asymmetric epoxidation followed by esterification for the formation of a fully functionalized acyclic precursor, Corey–Bakshi–Shibata reduction, and ring-closing metathesis, respectively.

Key words

antibiotic macrolide - (–)-5,6-dihydrocineromycine B - Sharpless asymmetric epoxidation - CBS reduction - ring-closing metathesis
 

  • References and Notes

    • 1a Galm U, Hager MH, Lanen SG. V, Ju J, Thorson JS, Shen B. Chem. Rev. 2005; 105: 739
      CrossrefPubMed
    • 1b Zhang H, Wang Y, Pfeifer BA. Mol. Pharm. 2008; 5: 212
      Crossref
  • 2 Schiewe HJ, Zeeck A. J. Antibiot. 1999; 52: 635
    Crossref
    • 3a Tanner D, Somfai P. Tetrahedron 1987; 43: 4395
      Crossref
    • 3b Takahashi T, Watanabe H, Kitahara T. Tetrahedron Lett. 2003; 44: 9219
      Crossref
    • 4a Tietze LF, Völkel L. Angew. Chem. Int. Ed. 2001; 40: 901
      Crossref
    • 4b Li G, Yang X, Zhai H. J. Org. Chem. 2009; 74: 1356
      Crossref
    • 5a Reddy GV, Kumar RS. C, Babu KS, Rao JM. Tetrahedron Lett. 2009; 50: 4117
      Crossref
    • 5b Reddy GV, Kumar RS. C, Sreedhar E, Babu KS, Rao JM. Tetrahedron Lett. 2010; 51: 1723
      Crossref
  • 6 Hayashi Y, Yamaguchi H, Toyoshima M, Okado K, Toyo T, Shoji M. Org. Lett. 2008; 10: 1405
    Crossref
  • 7 Gao Y, Hanson RM, Klunder JM, Ko SY, Masamune H, Sharpless KB. J. Am. Chem. Soc. 1987; 109: 5765
    Crossref
  • 8 Lee AW. M. J. Chem. Soc., Chem. Commun. 1984; 578
  • 9 Frigerio M, Santagostino M. Tetrahedron Lett. 1994; 35: 8019
    Crossref
  • 10 Wadsworth WS. Jr, Emmons WD. J. Am. Chem. Soc. 1961; 83: 1733
    Crossref
  • 11 Oikawa Y, Yoshioka T, Yonemitsu O. Tetrahedron Lett. 1982; 23: 885
    Crossref
    • 12a Dess DB, Martin JC. J. Am. Chem. Soc. 1991; 113: 7277
      Crossref
    • 12b Dess DB, Martin JC. J. Am. Chem. Soc. 1983; 105: 4155
      Crossref
  • 13 Furlan RL. E, Mata EG, Mascaretti OA, Pena C, Coba MP. Tetrahedron 1998; 54: 13023
    Crossref
  • 14 Sabitha G, Reddy CN, Gopal P, Yadav JS. Tetrahedron Lett. 2010; 51: 5736
    Crossref
  • 15 Tius MA, Fauq AH. J. Org. Chem. 1983; 48: 4131
    Crossref
    • 16a Mori K, Nomi H, Chuman T, Kohno M, Kato K, Noguchi M. Tetrahedron 1982; 38: 3705
      Crossref
    • 16b Shimizu Y, Kiyota H, Oritani T. Tetrahedron Lett. 2000; 41: 3141
      Crossref
  • 17 Nicolaou KC, Papahatjis DP, Claremon DA, Dolle RE. J. Am. Chem. Soc. 1981; 103: 6967
    Crossref
  • 18 Koert U, Wagner H, Pidun U. Chem. Ber. 1994; 127: 1447
    Crossref
  • 19 Martinelli MJ, Nayyar NK, Moher ED, Dhokte UP, Pawlak JM, Vaidyanathan R. Org. Lett. 1999; 1: 447
    Crossref
  • 20 Suzuki T, Saimoto H, Tomioka H, Oshima K, Nozaki H. Tetrahedron Lett. 1982; 23: 3597
    Crossref
  • 21 Inanaga J, Hirata K, Saeki H, Katsuki T, Yamaguchi M. Bull. Chem. Soc. Jpn. 1979; 52: 1989
    Crossref
    • 22a Corey EJ, Bakshi RK, Shibata S. J. Am. Chem. Soc. 1987; 109: 5551
      Crossref
    • 22b Corey EJ, Helal CJ. Angew. Chem. Int. Ed. 1998; 37: 1986
      CrossrefPubMed
  • 23 The diastereomeric excess of the allylic alcohol 5 was determined by HPLC [YMC CYNAO column, 250 × 4.6 mm, 5μ; eluent, MeCN–H2O (50:50), 10 μL injection volume, flow rate 1.0 mL/min; t R = 15.50 and 17.09 min].
    • 24a Nicolaou KC, Bulger PG, Sarlah D. Angew. Chem. Int. Ed. 2005; 44: 4490
    • 24b Jin J, Chen Y, Li Y, Wu J, Dai W.-M. Org. Lett. 2007; 9: 2585
      Crossref
    • 24c Park PK, O’Mally SJ, Schmidt DR, Leighton JL. J. Am. Chem. Soc. 2006; 128: 2796
      Crossref
    • 24d Ko K.-S, Alexander MD, Fontaine SD, Biggs-Houck JE, Clair JJ. L, Burkart MD. Org. Biomol. Chem. 2010; 8: 5159
      Crossref
  • 25 Spectral Data for Representative New Compounds Compound 9: colorless oil; [α]D 25 –5.5 (c 1, CHCl3). IR (KBr): 3399, 2933, 1612, 1513, 1248, 1035, 772 cm–1. 1H NMR (300 MHz, CDCl3): δ = 7.17 (d, 2 H, J = 8.30 Hz), 6.80 (d, 2 H, J = 9.00 Hz), 4.38 (s, 2 H), 3.74 (s, 3 H), 3.40 (t, 2 H, J = 5.20 Hz), 3.35–3.21 (m, 2 H), 1.70–1.39 (m, 4 H), 1.06 (s, 3 H). 13C NMR (75 MHz, CDCl3): δ = 159.1, 129.2, 113.6, 72.5, 72.4, 70.4, 69.5, 54.8, 35.2, 24.0, 23.1. ESI-MS: m/z = 277 [M + Na]+. ESI-HRMS: m/z calcd for C14H22NaO4: 277.1416; found: 277.1410. Compound 16: colorless oil; [α]D 25 +13.7 (c 1, CHCl3). IR (KBr): 3446, 2926, 1722, 1655, 1513, 1219, 1035, 772 cm–1. 1H NMR (300 MHz, CDCl3): δ = 7.19 (d, 2 H, J = 8.49 Hz), 6.92–6.77 (m, 3 H), 5.97 (d, 1 H, J = 15.67 Hz), 4.40 (s, 2 H), 4.16 (q, 2 H, J = 7.17, 14.16 Hz), 3.77 (s, 3 H), 3.47–3.32 (m, 3 H), 1.75–1.56 (m, 4 H), 1.33–1.22 (m, 6 H). 13C NMR (75 MHz, CDCl3): δ = 166.3, 159.1, 154.4, 129.7, 129.1, 118.9, 113.6, 72.6, 72.1, 70.0, 59.9, 54.8, 39.5, 28.1, 24.3, 14.3. ESI-MS: m/z = 345 [M + Na]+. ESI-HRMS: m/z calcd for C18H26NaO5: 345.1678; found: 345.1667. Compound 17: colorless oil; [α]D 25 +10.6 (c 1, CHCl3). IR (KBr): 3424, 2955, 1720, 1656, 1459, 1299, 1061, 772 cm–1. 1H NMR (300 MHz, CDCl3): δ = 6.83 (d, 1 H, J = 15.1 Hz), 5.88 (d, 1 H, J = 15.1 Hz), 4.18 (q, 2 H, J = 6.79, 14.35 Hz), 3.59 (t, 2 H, J = 6.04 Hz), 1.67–1.52 (m, 4 H), 1.39 (s, 3 H), 1.31 (t, 3 H, J = 6.79 Hz) 0.97 (t, 9 H, J = 8.30, 15.86 Hz), 0.61 (q, 6 H, J = 7.55, 15.86 Hz). 13C NMR (75 MHz, CDCl3): δ = 166.4, 154.4, 119.0, 75.1, 62.9, 60.2, 39.8, 27.9, 27.4, 14.4, 7.2, 6.8. ESI-MS: m/z = 339 [M + Na]+. ESI-HRMS: m/z calcd for C16H32NaO4Si: 339.1968; found: 339.1961. Compound 6: colorless oil; [α]D 25 –13.5 (c 1, CHCl3). IR (KBr): 3414, 2924, 1706, 1454, 1219, 1018, 770 cm–1. 1H NMR (300 MHz, CDCl3): δ = 6.92 (d, 1 H, J = 15.86 Hz), 5.95 (d, 1 H, J = 15.10 Hz), 5.91 (s, 1 H), 5.73 (s, 1 H), 2.83–2.69 (m, 1 H), 2.66–2.52 (m, 1 H), 1.95–1.81 (m, 5 H), 1.43 (s, 3 H), 0.97 (t, 9 H, J = 8.30 Hz), 0.61 (q, 6 H, J = 7.55, 15.86 Hz). 13C NMR (75 MHz, CDCl3): δ = 200.6, 172.0, 156.7, 144.6, 124.1, 118.8, 74.8, 37.0, 31.9, 28.2, 17.8, 7.2, 6.7. ESI-MS: m/z = 349 [M + Na]+. ESI-HRMS: m/z calcd for C17H30NaO4Si: 349.1811; found: 349.1820. Compound 11: colorless oil, [α]D 25 –2.5 (c 1, CHCl3). 1H NMR (300 MHz, CDCl3): δ = 7.79 (d, 2 H, J = 7.90 Hz), 7.34 (d, J = 7.90 Hz), 4.19–4.13 (m, 1 H), 4.03–3.96 (m, 2 H), 3.84 (q, 1 H, J = 6.30, 14.30 Hz), 3.58 (t, 1 H, J = 7.10 Hz), 2.45 (s, 3 H), 1.96–1.87 (m, 1 H), 1.31 (s, 3 H), 1.27 (s, 3 H), 0.90 (d, 3 H, J = 7.10 Hz). 13C NMR (75 MHz, CDCl3): δ = 144.6, 132.9, 129.7, 127.8, 109.0, 76.3, 72.2, 67.6, 37.0, 26.5, 25.3, 21.5, 12.8. ESI-MS: m/z = 337 [M + Na]+. ESI-HRMS: m/z calcd for C15H22NaO5S: 337.1086; found: 337.1091. Compound 7: colorless oil; [α]D 25 –12.8 (c 1, CHCl3). 1H NMR (300 MHz, CDCl3): δ = 5.85–5.65 (m, 1 H), 5.05–4.85 (m, 2 H), 3.62 (pent, 1 H, J = 6.04, 12.08, 18.12 Hz), 2.27–2.06 (m, 1 H), 2.05–1.86 (m, 2 H), 1.66–1.42 (m, 1 H), 1.23–1.13 (m, 1 H), 1.10 (d, 3 H, J = 6.04 Hz), 0.87 (d, 3 H, J = 6.79 Hz). 13C NMR (75 MHz, CDCl3): δ = 138.73, 114.53, 71.26, 39.41, 31.73, 31.50, 19.39, 14.50. Compound 31: colorless oil; [α]D 25 –17.2 (c 1, CHCl3). 1H NMR (300 MHz, CDCl3): δ = 6.78 (d, 1 H, J = 15.70 Hz), 5.93–5.84 (m, 2 H), 5.77–5.69 (m, 2 H), 5.02–4.38 (m, 3 H), 2.80–2.69 (m, 1 H), 2.67–2.58 (m, 1 H), 2.21–2.09 (m, 1 H), 2.06–1.97 (m, 1 H), 1.91–1.83 (m, 5 H), 1.79–1.69 (m, 1 H), 1.56–1.45 (m, 1 H), 1.41 (s, 3 H), 1.27–1.23 (m, 1 H), 1.20 (d, 3 H, J = 6.87 Hz), 0.96 (t, 9 H, J = 7.85 Hz), 0.92 (d, 3 H, J = 6.87 Hz), 0.61 (q, 6 H, J = 7.85, 15.70 Hz). 13C NMR (75 MHz, CDCl3): δ = 201.47, 166.14, 153.78, 144.47, 138.58, 124.34, 119.72, 114.63, 74.67, 74.17, 37.26, 36.80, 32.09, 31.78, 31.29, 28.09, 17.73, 16.07, 14.60, 7.12, 6.71. ESI-MS: m/z = 459 [M + Na]+. ESI-HRMS: m/z calcd for C25H44NaO4Si: 459.2907; found: 459.2910. Compound 5: colorless oil; [α]D 25 –21.7 (c 1, CHCl3). 1H NMR (300 MHz, CDCl3): δ = 6.86 (d, 1 H, J = 15.48 Hz), 5.93–5.84 (m, 2 H), 5.91 (d, 1 H, J = 15.48 Hz), 5.87–5.69 (m, 1 H), 5.07–4.81 (m, 5 H), 4.02 (t, 1 H, J = 5.28 Hz), 2.30–2.30 (m, 1 H), 2.23–1.93(m, 2 H), 1.69 (s, 3 H), 1.64–1.44 (m, 4 H), 1.38 (s, 3 H), 1.30–1.23 (m, 2 H), 1.19 (d, 3 H, J = 6.7 Hz), 0.96 (t, 9 H, J = 7.55 Hz), 0.92 (d, 3 H, J = 6.79 Hz), 0.61 (q, 6 H, J = 7.55, 15.86 Hz). 13C NMR (75 MHz, CDCl3): δ = 166.17, 154.27, 147.27, 128.58, 127.58, 126.56, 114.75, 111.27, 75.81, 74.96, 74.10, 39.02 36.83, 31.81, 31.34, 29.79, 29.11, 27.71, 17.64, 16.12, 14.68, 7.16, 6.79. ESI-MS: m/z 461 [M + Na]+. ESI-HRMS: m/z calcd for C25H46NaO4Si: 461.3063; found: 461.3044.